Nicotine replacement therapy (NRT), the antidepressant bupropion, and the drug varenicline can help smokers quit, according to a new systematic review published in The Cochrane Library.
Nicotine replacement therapy (NRT), the antidepressant bupropion, and the drug varenicline can help smokers quit, according to a new systematic review published in The Cochrane Library.
Additionally, the review found that cytisine, licensed for smoking cessation in Russia, holds potential as an effective and affordable treatment.
Researchers from the University of Oxford, Oxford, U.K., conducted the review. They collected evidence from 267 studies that had taken place between 2008 and 2012 and involved 101,804 people. The studies examined licensed and unlicensed smoking cessation products, comparing them against each other and placebos. A smoking cessation attempt was considered successful if a person stopped smoking for 6 months or longer.
The review found that the odds of a smoker quitting were 80% higher with one of the NRTs or bupropion than with placebo, and two to three times higher with varenicline versus placebo. Varenicline was about 50% more effective than any single NRT formulation, such as patches, gum, sprays, lozenges, and inhalers. However, combining two of the NRTs was equally effective as varenicline.
“This review provides strong evidence that the three main treatments, nicotine replacement therapy, bupropion, and varenicline, can all help people to stop smoking,” said lead researcher Kate Cahill, Department of Primary Care Health Sciences, University of Oxford.
The review also found that cytisine improved a smoker’s chances of quitting four-fold.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More